|
|
商品名 |
|
|
商品名、賦形剤は国、製薬会社ごとに異なることがあります
|
|
Alfast |
ブラジル |
|
Alfenta |
アメリカ, イラン, ペルー |
|
Alfentanil |
アメリカ, イギリス, イラン, カナダ, コロンビア, チリ, デンマーク, ドイツ, フィンランド, フランス |
|
Alfiject |
イラン |
|
Limifen |
スペイン |
|
Rapifen |
アイルランド, イギリス, イラン, エジプト, オランダ, オーストリア, ギリシア, サウジアラビア, スイス, スウェーデン, スロベニア, チュニジア, デンマーク, ドイツ, ニュージーランド, ノルウェー, フィンランド, フランス, ベルギー, ポルトガル, ポーランド, マレーシア, ルクセンブルグ |
|
|
|
|
引用文献 : Alfentanil hydrochloride |
|
|
形式 |
出版物 |
| 59 |
雑誌 |
Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 299 |
雑誌 |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
雑誌 |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 319 |
雑誌 |
Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999. |
| 660 |
雑誌 |
Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 815 |
雑誌 |
Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634. |
| 921 |
雑誌 |
Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |
| 1625 |
雑誌 |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
| 1712 |
雑誌 |
Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
雑誌 |
Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
雑誌 |
Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
| 1803 |
雑誌 |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1861 |
雑誌 |
Levadoux E, Sautou V, Bazin JE, Schoeffler P, Chopineau J. Medical plastics: compatibility of alfentanil and propofol alone or mixed. Stability of the alfentanil-propofol mixture. Int J Pharm 1996 ; 127: 255-259. |
| 1925 |
雑誌 |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
| 2086 |
雑誌 |
Sharley NA, Burgess NG. Stability and compatibility of alfentanil hydrochloride and morphine sulfate in poypropylene syringes. J Pharm Pract and Res 2003 ; 33: 279-281. |
| 3380 |
雑誌 |
Eckle V-S, Heim E, Hahn M, Grasshoff C. Incompatibility of Piritramide with Cephalosporins. Ann Pharmacotherapy 2013 ;47:426-427. |
| 3502 |
実験 |
Propofol (Diprivan®) - Summary of Products Characteristics Astra Zeneca 2012 |
| 3504 |
実験 |
Parecoxib (Dynastat®) - Summary of Product Characteristics Pfizer 2012 |
| 3601 |
実験 |
Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012 |
| 4952 |
実験 |
Alfentanil 5 mg/ml solution for injection - Summary of Product Characteristics Updated 19-Oct-2022 | hameln pharma ltd Hameln pharma ltd 2022 |
| 4993 |
実験 |
MIVACRON 20 mg/10 ml, solution injectable (IV) - Résumé des caractéristiques du produit. ASPEN PHARMA TRADING LIMITED |
|
|